High-dose intravenous immunoglobulin therapy for eosinophilic granulomatosis with polyangiitis

Table 3 Diagnosis by ACR criteria at onset

	EGPA patients who received IVIG during initial treatment (n = 10)	EGPA patients who received IVIG on relapse after remission (n = 7)	P
Asthma (yes/no)	10/0	7/0	NS^*
Paranasal sinusitis (yes/no)	9/1	6/1	NS^*
Multiple polyneuropathy (yes/no)	10/0	7/0	NS^*
Pulmonary infiltrates (yes/no)	8/2	6/1	NS^*
Extravascular eosinophils (pathology) (yes/no)	10/0	7/0	NS^*
Eosinophilia in peripheral blood >10% (yes/no)	10/0	7/0	NS^*
ACR 5/6 (%)	30	57.1
ACR 6/6 (%)	70	42.9

ACR, American College of Rheumatology, EGPA, eosinophilic granulomatosis with polyangiitis; IVIG, intravenous immunoglobulin; NS, not significant.
All values are expressed as means ± 1 SD.
Values of P < 0.05 were considered statistically significant.
*: Chi-squared testing revealed no significant differences between the two groups.

ISSN: 2045-7022